Solid lipid nanoparticles (SLN) for controlled drug delivery. II. Drug incorporation and physicochemical characterization.
Solid lipid nanoparticles (SLN) for controlled drug delivery. II. Drug incorporation and physicochemical characterization.
复制标题
DOI：
10.1080/026520499289185
复制
发表时间：
1999-03
影响因子：
3.9
通讯作者：
C. Schwarz;W. Mehnert
中科院分区：
文献类型：
--
作者：
C. Schwarz;W. Mehnert
固体脂质纳米粒（Solid lipid nanoparticles，SLN）是一种用于药物控释的胶体载体系统。采用亲脂性模型药物丁卡因和依托咪酯，研究了最大载药量、包封率、药物掺入对SLN大小、Zeta电位（电荷）和长期物理稳定性的影响。可以实现高达10%的药物载量，同时保持物理稳定的纳米颗粒分散体。与不含药物的SLN相比，药物的掺入对粒径和zeta电位没有影响或影响很小。因此，先前为无药物SLN分散体建立的优化生产参数可以转移到载药系统中，以促进产品开发。
Solid lipid nanoparticles (SLN) are a colloidal carrier system for controlled drug delivery. The lipophilic model drugs tetracaine and etomidate were incorporated to study the maximum drug loading, entrapment efficacy, effect of drug incorporation on SLN size, zeta potential (charge) and long-term physical stability. Drug loads of up to 10% could be achieved whilst simultaneously maintaining a physically stable nanoparticle dispersion. Incorporation of drugs showed no or little effect on particle size and zeta potential compared to drug-free SLN. The optimized production parameters previously established for drug-free SLN dispersions can therefore be transferred to drug-loaded systems to facilitate product development.